Chemotherapy-induced cognitive dysfunction: a clearer picture

Area of Science:

• Oncology
• Neuroscience
• Hematology

Background:

• Chemotherapy-associated cognitive dysfunction (CACD) affects cancer patients, with anemia being a potential contributing factor.
• Erythropoietin (EPO) regulates red blood cell production and is known to have neuroprotective roles.
• Recombinant human EPO (epoetin alfa) effectively treats chemotherapy-related anemia and improves quality of life.

Purpose of the Study:

• To explore the potential neuroprotective effects of epoetin alfa in mitigating chemotherapy-associated cognitive dysfunction.
• To investigate the role of erythropoietin in neural cells and its response to injury.

Main Methods:

• Review of existing data on chemotherapy-induced cognitive dysfunction and anemia.
• Examination of studies on epoetin alfa's effects on quality of life in anemic cancer patients.
• Analysis of research on erythropoietin expression and function in neural tissues and animal models of injury.

Main Results:

• Chemotherapy-related anemia is linked to cognitive dysfunction.
• Epoetin alfa treatment improves quality of life in anemic cancer patients.
• EPO and its receptor are present in brain neural cells, with expression increasing after injury; epoetin alfa shows neuroprotection in animal models.

Conclusions:

• Epoetin alfa's established efficacy in treating anemia and improving quality of life warrants further investigation for its potential to prevent chemotherapy-associated cognitive dysfunction.
• Ongoing studies aim to confirm if epoetin alfa can offer neuroprotection against cognitive impairment in breast cancer patients receiving adjuvant chemotherapy.